Loose Skin After GLP-1 Weight Loss: What Determines It, and What Actually Helps

The short version

Start with the gap, because it shapes everything below: no study has examined loose skin in people who lost weight on a GLP-1. A search of the published literature for excess skin or skin laxity against this drug class returns nothing.

What exists instead is a substantial literature on excess skin after bariatric surgery. It is a fair comparison — a comparable amount of weight, lost at a comparable speed, in a comparable population — and it is a comparison, not a study of these medicines. Every figure on this page carries that qualifier.

Read that way, the evidence is reasonably clear about three things. Loose skin is very common after large weight loss. How much you get is driven mostly by how much weight you lose, not by anything you did wrong. And of the interventions people are sold, only one has outcome data behind it, and that data is not randomized.

How common, and where

The largest determinant study surveyed 360 patients — 250 women and 110 men — at least a year after bariatric surgery, after a mean weight loss of 35.2 kg. 92.8% reported problems with redundant skin, concentrated on the abdomen, upper arms and rear, and it impaired daily physical activity in about half of them¹.

A separate Swedish survey found the most frequently reported site of excess skin was the upper arms in women, at 91%, versus the abdomen in men, at 78%. Women reported significantly more excess skin, more problems and more discomfort than men, and there was a strong correlation between how much excess skin someone had and how much it bothered them, at every body part².

Two things are worth taking from that. It is close to universal after weight loss of this size, so it is not a personal failure of skin quality. And it is not evenly distributed — the arms, abdomen and buttocks carry it, which is also where the gluteofemoral volume loss shows up.

What actually determines how much you get

This is the part most articles skip, because it requires a study that modelled it rather than counted it.

On multivariate analysis, excess skin was independently associated with female sex, the amount of weight lost, and the change in BMI¹. The dose-response is the useful bit:

That last row is the one to hold onto. The authors' own conclusion is that the change in BMI and the amount of weight lost, not BMI alone, should be the basis for grading these problems¹. In plain terms: it is the size of the drop that determines the skin, not the size you started at.

Which is why this matters for GLP-1s specifically. In the SURMOUNT-1 DXA substudy, tirzepatide produced a 21.3% reduction in body weight and a 33.9% reduction in fat mass over 72 weeks, against 5.3% and 8.2% on placebo³. A systematic review of 35 randomized trials found the same pattern across the drug class: weight loss consistently larger than placebo or lifestyle comparators, consistently accompanied by reductions in fat mass — and in the comparator groups, a median weight loss of just −2.5%⁴.

These medicines have not introduced a new skin problem. They have made the amount of weight loss that produces one available to far more people, and faster. Age and genetics are commonly invoked as well, and are entirely plausible — but neither was modelled in the study above, so I am not going to give you a number for them.

What helps, ranked by how much evidence there is

Body contouring surgery — the only option with outcome data. A 2026 systematic review and meta-analysis pooled 15 studies of 7,339 patients comparing bariatric surgery alone with bariatric surgery plus body contouring. On the BODY-Q instrument, the contouring group scored substantially better across body image, physical, psychological, sexual and social function, with a mean difference of 16.07 (95% CI 12.14 to 20.0)⁵.

The caveat is structural and the authors flag it: none of the 15 studies was randomized, and they were assessed with a risk-of-bias tool built for non-randomized research⁵. People who pursue and can afford reconstructive surgery differ systematically from people who do not. The same review found that among patients who had bariatric surgery alone, those who wanted contouring already reported lower body satisfaction — which tells you the groups were not alike to begin with. The direction of benefit is believable. The size of it is probably flattered.

Losing weight more gradually — mechanistically sound, never tested. Skin remodels slowly, and a slower drop gives it more time. No trial has randomized anyone to a slower rate to see whether the skin ends up better, so this is reasoning rather than evidence.

Resistance training — helps the body, not the skin. Building muscle changes what sits underneath, which changes how loose skin drapes. It does not remove skin. Worth doing for the lean-mass reasons; not a treatment for this.

Topical products — no supporting evidence for the body. The study most often cited in this space examined facial volume in 29 completers over 12 weeks with no control group and no placebo cream, which cannot separate the product from a moisturiser or the passage of time⁶. It is discussed properly on the Ozempic face page. Nothing comparable exists for the abdomen or arms, and results on a face would not transfer to skin that has been stretched around 30 kg.

Collagen supplements, "skin-tightening" devices, wraps. No evidence in this population. Not weak evidence — none.

The part that is not cosmetic

Redundant skin impaired daily physical activity in roughly half of the patients in the Finnish survey¹, and skin that folds can chafe, macerate and become infected. If a fold is persistently sore, weeping, or smells, that is a clinical problem worth showing to a clinician rather than managing privately — it is treatable, and it is also the sort of thing that makes a surgical referral reasonable rather than aesthetic.

Where this sits on the evidence scale

That large weight loss produces loose skin: strong. 92.8% in the largest determinant survey, with abdomen, arms and buttocks the dominant sites^1,2.

That the amount lost drives how much you get: moderate to strong. Independently associated on multivariate analysis, with a clear dose-response across weight-loss and ΔBMI thresholds¹.

That this applies to GLP-1 weight loss: inferred, not demonstrated. The mechanism is amount and speed, and these drugs deliver both^3,4 — but the excess-skin research is entirely post-bariatric, and nobody has surveyed a GLP-1 cohort.

That body contouring improves quality of life: moderate, and inflated. Large, consistent patient-reported gains across 15 studies, none of them randomized, in a group that self-selected⁵.

That anything non-surgical tightens body skin: no evidence. The one relevant trial was uncontrolled, twelve weeks long, and about faces⁶.

What would change this page: a validated excess-skin questionnaire administered to people 12 months into GLP-1 treatment. The instruments already exist and have been used for two decades in bariatric research. Turning them on this population would take one study, and would replace this entire page's worth of careful analogy with an actual answer.